Related Experiment Video
Updated: Sep 11, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
High Propensity for Multidrug-Resistant Pneumococcal Shedding Among Adults Living With HIV on Stable Antiretroviral
Lusako L Sibale1,2,3, Newton Kalata1, Ndaona Mitole1
1Infection and Immunity Research Group, Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Background:
People living with human immunodeficiency virus (HIV; PLHIV) on antiretroviral therapy (ART) are still at risk of pneumococcal disease and have over 2-fold higher pneumococcal carriage prevalence than HIV-uninfected (HIV-) adults). Carriage is a risk factor for pneumococcal disease, antimicrobial resistance (AMR) emergence, and transmission. Therefore, we tested whether the high prevalence of pneumococcal carriage in PLHIV on ART is associated with increased bacterial density, shedding, and AMR.
Methods:
We recruited asymptomatic PLHIV on ART for >1 year (PLHIV-ART>1y) and HIV- adults. Nasopharyngeal swab samples were collected on days 3, 7, 14, 21, and 28, followed by monthly collections for 12 months, while shedding samples were collected on days 3, 21, and 28. Peripheral blood samples were collected on day 3 to measure CD4 cell count and HIV viral load. Pneumococcal carriage density and shedding were assessed using standard bacterial culture, multiple carriage was detected using whole-plate sweep sequencing, and AMR profiling was conducted using disk diffusion and Etest.
Results:
PLHIV-ART>1y had a higher propensity for high-density carriage (adjusted odds ratio, 1.67 [95% confidence interval (CI), 1.07-2.60]; P = .02). Moreover, PLHIV-ART>1y are more likely to shed pneumococci than HIV- adults (adjusted odds ratio, 2.52 [95% CI, 1.06-6.00]; P = .04), with carriage density identified as an important risk factor for shedding (3.35 [1.55-7.24]; P = .002). Aerosol shed isolates from PLHIV-ART>1y were mostly multidrug resistant (18 of 29 [ 62%; 95% CI, 48%-77%]).
Conclusions:
These findings indicate that PLHIV-ART>1y remain at high risk of pneumococcal disease and could also be an important reservoir for shedding multidrug-resistant pneumococci.
Insights
People living with HIV on antiretroviral therapy have higher pneumococcal carriage density and shedding. This increases their risk of pneumococcal disease and makes them a reservoir for multidrug-resistant strains.
Area of Science:
- Infectious Diseases
- Microbiology
- Public Health
Background:
- People living with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) experience higher prevalence of pneumococcal carriage.
- Pneumococcal carriage is a risk factor for pneumococcal disease, antimicrobial resistance (AMR), and transmission.
Purpose of the Study:
- To investigate if high pneumococcal carriage in people living with HIV on ART is linked to increased bacterial density, shedding, and AMR.
- To assess the role of carriage density as a risk factor for pneumococcal shedding.
Main Methods:
- Recruited asymptomatic people living with HIV on ART for over 1 year (PLHIV-ART>1y) and HIV-negative adults.
- Collected nasopharyngeal and shedding samples over time, along with peripheral blood for CD4 count and HIV viral load.
- Assessed pneumococcal carriage density, shedding, multiple carriage, and AMR profiles using bacterial culture, sequencing, and antimicrobial susceptibility testing.
Main Results:
- PLHIV-ART>1y exhibited a higher propensity for high-density pneumococcal carriage (aOR, 1.67).
- PLHIV-ART>1y were more likely to shed pneumococci (aOR, 2.52), with carriage density being a significant risk factor for shedding (aOR, 3.35).
- A majority of aerosol shed isolates from PLHIV-ART>1y were multidrug-resistant (62%).
Conclusions:
- People living with HIV on ART remain at elevated risk for pneumococcal disease.
- These individuals may serve as a significant reservoir for shedding multidrug-resistant pneumococci, posing a public health concern.
More Related Videos
07:21Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
09:54Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
Published on: December 3, 2019
Related Concept Videos
Retrovirus Life Cycles
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...